OTCMKTS:ENZN Enzon Pharmaceuticals Q3 2025 Earnings Report $4.35 0.00 (0.00%) As of 10/6/2026 ProfileEarnings History Enzon Pharmaceuticals EPS ResultsActual EPS-$2.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEnzon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnzon Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/12/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Enzon Pharmaceuticals Earnings HeadlinesViskase Holdings (ENZN) RatiosJuly 18, 2026 | uk.investing.comEnzon Pharmaceuticals Amends and Extends Credit Agreement FacilitiesApril 21, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Enzon Pharmaceuticals Announces New Permanent Financial LeadershipApril 15, 2026 | tipranks.comEnzon Completes Merger and Rebrands as Viskase HoldingsMarch 26, 2026 | tipranks.comEnzon Pharmaceuticals Inc.March 25, 2026 | barrons.comSee More Enzon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enzon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enzon Pharmaceuticals and other key companies, straight to your email. Email Address About Enzon PharmaceuticalsEnzon Pharmaceuticals (OTCMKTS:ENZN), Inc. was a biopharmaceutical company focused on developing and commercializing medicines using its proprietary PEGylation technology. PEGylation attaches polyethylene glycol to therapeutic molecules to potentially extend their time in the body and improve treatment characteristics. The company’s historical product portfolio included ADAGEN (pegademase bovine), a treatment for adenosine deaminase deficiency; ONCASPAR (pegaspargase), used in the treatment of acute lymphoblastic leukemia; and other PEGylated therapies developed independently or with pharmaceutical partners. Enzon also licensed its PEGylation technology to other companies for use in drug development. Enzon was based in Bridgewater, New Jersey, and served the biopharmaceutical and healthcare markets through products and technology partnerships. The company later significantly reduced its operations and pursued strategic alternatives, so historical descriptions of its business may not reflect an active operating pharmaceutical company today.View Enzon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
